魯婧 杜君
摘要:近年來肺心病的發(fā)病率逐年上升,以往認(rèn)為肺心病對(duì)心臟的影響主要以右心功能障礙為主,不影響左心功能,左心功能障礙主要為原發(fā)左心病變所致,但近年來不少文獻(xiàn)指出由慢阻肺長期發(fā)展引起的肺心病在早期即可合并左心功能障礙,主要以左室舒張功能障礙為主。本文主要從五個(gè)不同方面闡述由慢阻肺長期發(fā)展引起的肺心病患者左室舒張功能障礙的原因,結(jié)合相關(guān)文獻(xiàn)做一綜述。
關(guān)鍵詞:肺心病;左室舒張功能障礙;慢阻肺
中圖分類號(hào):R541.5? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?文獻(xiàn)標(biāo)識(shí)碼:A? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?DOI:10.3969/j.issn.1006-1959.2019.04.019
文章編號(hào):1006-1959(2019)04-0054-03
Abstract:In recent years, the incidence of pulmonary heart disease has increased year by year. In the past, the influence of pulmonary heart disease on the heart was mainly due to right heart dysfunction, which did not affect left heart function. Left heart dysfunction was mainly caused by primary left heart disease, but in recent years, many literatures indicate that pulmonary heart disease caused by long-term development of chronic obstructive pulmonary disease can be combined with left ventricular dysfunction in the early stage, mainly with left ventricular diastolic dysfunction. This article mainly describes the causes of left ventricular diastolic dysfunction in patients with pulmonary heart disease caused by long-term development of chronic obstructive pulmonary disease from five different aspects, and summarizes the related literature.
Key words:Pulmonary heart disease;Left ventricular diastolic dysfunction;Chronic obstructive pulmonary disease
慢性肺源性心臟?。╟hronic corpulmonale heart disease),簡稱肺心病,是一種常見的慢性呼吸系統(tǒng)疾病,主要是慢阻肺長期發(fā)展的結(jié)果[1,2],占肺心病病因的80%~90%[3]。據(jù)調(diào)查顯示在中國肺心病的檢出率約為12%,并且其發(fā)病率目前仍呈上升的趨勢(shì)[4]。以往認(rèn)為肺心病是以右心功能障礙為主,不影響左心功能,左心功能障礙多為原發(fā)性左心病變所致,但近年來不少研究顯示,慢阻肺早期即可能合并有左心功能障礙,而且主要表現(xiàn)為左心舒張功能不全[5-7]。本文結(jié)合相關(guān)文獻(xiàn)對(duì)由慢阻肺長期發(fā)展引起的肺心病患者其左心舒張功能障礙的原因做一綜述。
1左心室舒張功能障礙的定義與影響
左心室舒張功能障礙是指在心動(dòng)周期中左心室在舒張?jiān)缙谥鲃?dòng)充盈及舒張晚期的順應(yīng)性下降,導(dǎo)致左心室在舒張期充盈受損,出現(xiàn)舒張功能的減退,左室舒張末壓升高,最終引起肺淤血[8]。研究顯示[9],在慢性心力衰竭患者中舒張性心力衰竭已經(jīng)成為了最常見的心衰形式,并且舒張功能減退在心臟疾病中廣泛存在,是引起患者產(chǎn)生一系列癥狀、體征的重要原因。一項(xiàng)基于社區(qū)人群的大型流行病學(xué)調(diào)查顯示[10],舒張功能減退是心衰發(fā)生的獨(dú)立預(yù)測(cè)因素,其與心衰患者預(yù)后不良密切相關(guān),并且在預(yù)測(cè)死亡率方面其較左室射血分?jǐn)?shù)(LVEF)價(jià)值更大,因此若能及時(shí)發(fā)現(xiàn)并干預(yù),將對(duì)患者的遠(yuǎn)期預(yù)后意義重大。
2肺心病左室舒張功能障礙的發(fā)病機(jī)制
2.1心臟生理結(jié)構(gòu)與右心功能的影響? 從心臟的生理結(jié)構(gòu)分析,左右心室在心包包裹下由室間隔隔開,其形態(tài)、功能和壓力相互作用、相互影響。任何一個(gè)心室的形態(tài)、功能改變,都將影響另一個(gè)心室的順應(yīng)性和幾何形狀。由慢阻肺長期發(fā)展引起的肺心病患者其右心功能的改變?cè)缇筒谎远髁?,其由于長期肺動(dòng)脈高壓,繼發(fā)右心室壓力增高,引起右心室代償性肥厚、擴(kuò)張,搏出量降低,收縮末期容量增加,最終導(dǎo)致右心功能障礙[1]。長期右心室功能不全,收縮末期容量增加,使室間隔在整個(gè)心動(dòng)周期中持續(xù)凸向左心室側(cè)并且出現(xiàn)室間隔代償性增厚,又由于心臟受心包生理性包裹的限制,將使左心室在舒張末期內(nèi)徑減小,導(dǎo)致左室充盈受限,前負(fù)荷降低,長期前負(fù)荷降低又將引起左室肥厚,順應(yīng)性下降,故長期右心功能障礙可影響左心功能,尤以左室舒張功能明顯[11,12]。
2.2病態(tài)肺循環(huán)、全身促炎癥狀態(tài)與冠脈微循環(huán)? Voelkel NF等研究者[13]認(rèn)為,病態(tài)肺循環(huán)和右心室高壓力狀態(tài)是一個(gè)綜合功能單位,二者相互作用、相互影響,肺循環(huán)的病態(tài)改變(病態(tài)肺循環(huán))是指肺小動(dòng)脈在形態(tài)和生理上均發(fā)生改變,其將直接影響心臟的健康。病態(tài)肺循環(huán)將產(chǎn)生各種循環(huán)細(xì)胞、細(xì)胞碎片、游離DNA及含外顯子的miRNA,其經(jīng)大部分肺血管及少量心輸出量進(jìn)入心臟的冠脈微循環(huán),并且由微循環(huán)的血管內(nèi)皮細(xì)胞攝取和處理。在正常情況下,正常的內(nèi)皮細(xì)胞微泡主要通過白介素1激活內(nèi)皮細(xì)胞,并且通過線粒體RNA的轉(zhuǎn)錄激活血管內(nèi)皮細(xì)胞中的血管生成程序,然而病態(tài)肺循環(huán)產(chǎn)生的一系列細(xì)胞及細(xì)胞碎片,在游離DNA及含外顯子的MiRNA的共同作用下,使內(nèi)皮細(xì)胞發(fā)生基因重組,導(dǎo)致心臟心室微循環(huán)血管變稀疏,心室細(xì)胞代謝異常,心肌纖維化增加。有研究顯示[14],慢阻肺可導(dǎo)致C-反應(yīng)蛋白、IL-6、TNF-α等炎癥因子升高,使人處于全身促炎癥狀態(tài)。Paulus? WJ等[15]認(rèn)為,這種全身促炎癥狀態(tài)通過血液循環(huán)至冠脈微循環(huán),引起冠狀動(dòng)脈微血管內(nèi)皮細(xì)胞的氧化應(yīng)激,進(jìn)而引起氧化損傷,減弱心肌細(xì)胞中蛋白激酶G的活性,導(dǎo)致心肌細(xì)胞的被動(dòng)張力增加,引起心肌細(xì)胞增生肥大和成纖維細(xì)胞的增生,最終促進(jìn)了心室向心性重構(gòu)、心肌纖維化增加。心室肌纖維化增加,活動(dòng)度下降,進(jìn)而使心室舒張末壓升高,左室容量縮小,影響了心室充盈,使壓力與容量曲線左移,長期存在的壓力負(fù)荷過重進(jìn)而導(dǎo)致左室舒張功能障礙,甚至是射血分?jǐn)?shù)保留的心力衰竭。
2.3呼吸肌的泵效應(yīng)? 呼吸肌的泵效應(yīng)是指通過呼吸運(yùn)動(dòng)將體循環(huán)中的血液更有效運(yùn)回心臟,維持心臟的泵血,然而在肺心病患者中,呼吸肌萎縮、無力是十分常見的一種呼吸肌表現(xiàn)。有研究指出[16],適當(dāng)?shù)暮粑″憻捘芨行Ц纳坡璺位颊叩纳钯|(zhì)量、延長壽命。眾所周知,呼吸肌的運(yùn)動(dòng)是呼吸運(yùn)動(dòng)的基礎(chǔ),吸氣時(shí),胸腔容積加大,胸腔負(fù)壓值加大,使胸腔內(nèi)大靜脈和右心房擴(kuò)張,壓力下降,有利于靜脈血回流入右心房,呼吸肌無力會(huì)導(dǎo)致呼吸運(yùn)動(dòng)障礙,主動(dòng)吸氣能力減弱,胸腔內(nèi)負(fù)壓值減少,回心血量也相應(yīng)減少,呼吸肌的泵效應(yīng)減弱,引起心室舒張末期容積與壓力減小,主要表現(xiàn)為左心舒張功能不全。
2.4自主神經(jīng)調(diào)節(jié)異常? 自主神經(jīng)系統(tǒng)是指調(diào)節(jié)內(nèi)臟功能活動(dòng)的神經(jīng)系統(tǒng),其中自主神經(jīng)包括交感與副交感神經(jīng)兩部分,其可以調(diào)節(jié)心率、心肌收縮力、血壓、氣道平滑肌舒縮、粘膜下腺體分泌等,其中交感神經(jīng)張力增加,副交感神經(jīng)張力減弱和壓力感受器敏感性改變都將影響心臟的生理功能。由慢阻肺長期發(fā)展引起的肺心病患者長期低氧血癥與高碳酸血癥反復(fù)刺激頸動(dòng)脈外周化學(xué)感受器,引起頸動(dòng)脈化學(xué)感受器敏感性降低;并且其阻塞性通氣功能障礙又使得胸內(nèi)壓力波動(dòng)增加,胸內(nèi)壓力大幅度波動(dòng)引起壓力感受器變化。這一系列變化使機(jī)體對(duì)交感神經(jīng)和副交感神經(jīng)刺激的反應(yīng)能力減弱(自主神經(jīng)反射減弱),最終會(huì)導(dǎo)致靜息心率增加,而心率的增加可直接導(dǎo)致心臟舒張期時(shí)間相對(duì)縮短,進(jìn)而影響左心舒張功能[17]。
2.5大氣污染中的PM2.5與香煙煙霧? 中國成人肺部健康研究顯示[18],大氣污染中的細(xì)顆粒物(PM2.5)濃度與由慢阻肺長期發(fā)展的肺心病顯著相關(guān);同樣也有研究指出[19,20],香煙暴露為心血管疾病和慢阻肺共同的危險(xiǎn)因素。據(jù)相關(guān)文獻(xiàn)報(bào)道[21,22],隨著呼吸運(yùn)動(dòng)而沉積在肺內(nèi)的香煙煙霧和達(dá)到一定濃度的細(xì)顆粒物(PM2.5)經(jīng)氣體交換進(jìn)入血液循環(huán)后,通過誘導(dǎo)系統(tǒng)內(nèi)氧化應(yīng)激和炎癥反應(yīng)引起血管內(nèi)皮細(xì)胞功能紊亂,氧自由基生成增加、清除減少,從而大量活性氧自由基釋放入血,引起血管痙攣收縮導(dǎo)致血壓升高,心臟收縮期后負(fù)荷增加,心肌細(xì)胞代償性增生肥大、心肌間質(zhì)纖維化,繼而引起左心室向心性重構(gòu),心室肌順應(yīng)性下降,心室充盈不良,最終導(dǎo)致左心室舒張功能下降。
2.6其他? 相關(guān)研究顯示[23],雌激素通過調(diào)節(jié)腎素-血管緊張素-酸固酮系統(tǒng)和NO合成酶系統(tǒng)的細(xì)胞內(nèi)信號(hào)通路,抑制心肌肥厚,降低心肌細(xì)胞被動(dòng)張力,增加心肌順應(yīng)性,從而抑制左心舒張功能不全,若體內(nèi)雌激素水平降低將使其對(duì)心臟舒張功能的保護(hù)能力降低。另外隨著年齡的不斷增大,體內(nèi)各個(gè)器官存在生理性功能減退,心肌同樣也同樣因年齡增加而纖維化,心肌順應(yīng)性下降,左心室充盈壓升高,導(dǎo)致左心舒張功能不全[24]。
3總結(jié)及展望
在肺心病患者心功能的研究中,以往學(xué)者們大多集中在右心功能的改變上,但近年來也有不少文獻(xiàn)反映了由慢阻肺長期發(fā)展引起的肺心病在發(fā)病早期亦合并有左心功能不全,主要表現(xiàn)為左室舒張功能障礙。本文主要從心臟生理結(jié)構(gòu)與右心功能的影響,病態(tài)肺循環(huán)、全身促炎癥狀態(tài)與冠脈微循環(huán),呼吸肌的泵效應(yīng),大氣污染中的PM2.5與香煙煙霧等幾個(gè)方面闡述了由慢阻肺長期發(fā)展引起的肺心病其左室舒張功能障礙的可能原因。眾所周知,近年來肺心病患者發(fā)病率逐年上升,同時(shí)也伴隨著致殘、致死率及社會(huì)經(jīng)濟(jì)壓力的上升,所以在關(guān)注肺心病右心功能障礙的同時(shí)關(guān)注左心功能改變,對(duì)患者制定個(gè)體化治療方案將有助于臨床治療和康復(fù),提高患者生活質(zhì)量及生存率。
參考文獻(xiàn):
[1]Zangiabadi A,De Pasquale CG,Sajkov D.Pulmonary hypertension and right heart dysfunction in chronic lung disease[J].Biomed Res Int,2014(24):739674.
[2]Stone IS,Barnes NC,Petersen SE.Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease?[J].Heart(British Cardiac Society),2012,98(14):1055-1062.
[3]葛均波,徐永健.內(nèi)科學(xué)[M].第8版.北京:人民衛(wèi)生出版社,2013.
[4]Xu W,Yao J,Chen L.Anxiety in Patients with Chronic Cor Pulmonale and Its Effect on Exercise Capacity[J].Iranian Journal of Public Health,2016,45(8):1004-1011.
[5]Nojiri T,Yamamoto K,Maeda H,et al.Effects of inhaled tiotropium on left ventricular diastolic function in chronic obstructive pulmonary disease patients after pulmonary resection[J].Ann Thorac Cardiovasc Surg,2012,18(3):206-211.
[6]Lopez-Sanchez M,Munoz-Esquerre M,Huertas D,et al.High Prevalence of Left Ventricle Diastolic Dysfunction in Severe COPD Associated with A Low Exercise Capacity: A Cross-Sectional Study[J].PLoS One,2013,8(6):e68034.
[7]Caram LM,F(xiàn)errari R,Naves CR,et al.Association between left ventricular diastolic dysfunction and severity of chronic obstructive pulmonary disease[J].Clinics(Sao Paulo),2013,68(6):772-776.
[8]Jeong EM,Dudley SC Jr.Diastolic dysfunction[J].Circ J,2015,79(3):470-477.
[9]Nicoara A,Jones-Haywood M.Diastolic heart failure: diagnosis and therapy[J].Curr Opin Anaesthesiol,2016,29(1):61-67.
[10]Aljaroudi W,Alraies MC,Halley C,et al.Impact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction[J].Circulation,2012,125(6):782-788.
[11]Gurudevan SV,Malouf PJ,Auger WR,et al.Abnormal left ventricular diastolic filling in chronic thromboembolic pulmonary hypertension:true diastolic dysfunction or left ventricular underfilling?[J].Journal of the American College of Cardiology,2007,49(12):1334-1339.
[12]Rosenkranz S,Gibbs JS,Wachter R,et al.Left ventricular heart failure and pulmonary hypertension[J].European Heart Journal,2016,37(12):942-954.
[13]Voelkel NF,Bogaard HJ,Gomez-Arroyo J.The need to recognize the pulmonary circulation and the right ventricle as an integrated functional unit: facts and hypotheses (2013 Grover Conference series)[J].Pulmonary Circulation,2015,5(1):81-89.
[14]Khan NA,Daga MK,Ahmad I,et al.Evaluation of BODE index and its relationship with systemic inflammation mediated by proinflammatory biomarkers in patients with COPD[J].Journal of Inflammation Research,2016(9):187-198.
[15]Paulus WJ,Tschope C.A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation[J].Journal of the American College of Cardiology,2013,62(4):263-271.
[16]Majewska-Pulsakowska M,Wytrychowski K,Rozek-Piechura K.The Role of Inspiratory Muscle Training in the Process of Rehabilitation of Patients with Chronic Obstructive Pulmonary Disease[J].Adv Exp Med Biol,2016,885(1):47-51.
[17]Florea VG,Cohn JN.The autonomic nervous system and heart failure[J].Circulation Research,2014,114(11):1815-1826.
[18]Wang C,Xu J,Yang L,et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study[J].Lancet,2018,391(10131):1706-1717.
[19]Murray LA,Dunmore R,Camelo A,et al.Acute cigarette smoke exposure activates apoptotic and inflammatory programs but a second stimulus is required to induce epithelial to mesenchymal transition in COPD epithelium[J].Respiratory Research,2017,18(1):82.
[20]Lubin JH,Couper D,Lutsey PL,et al.Risk of Cardiovascular Disease from Cumulative Cigarette Use and the Impact of Smoking Intensity[J].Epidemiology(Cambridge, Mass.),2016,27(3):395-404.
[21]Anderson C,Majeste A,Hanus J,et al.E-Cigarette Aerosol Exposure Induces Reactive Oxygen Species, DNA Damage, and Cell Death in Vascular Endothelial Cells[J]. Toxicological Sciences,2016,154(2):332-340.
[22]Jernigan NL,Naik JS,Weise-Cross L,et al.Contribution of reactive oxygen species to the pathogenesis of pulmonary arterial hypertension[J].PLoS One,2017,12(6):e0180455.
[23]Jessup JA,Wang H,MacNamara LM,et al.Estrogen therapy,independent of timing, improves cardiac structure and function in oophorectomized mRen2.Lewis rats[J].Menopause,2013,20(8):860-868.
[24]Aboulhoda BE.Age-related remodeling of the JAK/STAT/SOCS signaling pathway and associated myocardial changes: From histological to molecular level[J].Ann Anat,2017,214(7):21-30.
收稿日期:2018-11-25;修回日期:2018-12-15
編輯/王海靜